Bacillus coagulans GBI-30, 6086
Safety profile
3 studies reporting safety data
Across 3 clinical studies, no specific adverse events were quantitatively reported for Bacillus coagulans GBI-30, 6086. The probiotic was described as well tolerated in all studies, with no treatment-related or serious adverse events reported. One study noted an improvement in chronic gastrointestinal symptoms, further supporting a favorable tolerability profile.
Caveats: Evidence is limited to short-term studies (up to 8 weeks); long-term safety not established. Studies were powered for efficacy, not safety — rare adverse events may not be detected.
- Reduced Flatulence
- Reduced C-Reactive Protein Levels
- Reduced Nasal Congestion
- Improved Lactose Digestion
- Increased CD4+ T Cell Count
- Reduced Interleukin-1β Levels
- Reduced Abdominal Pain
- Improved Stool Consistency
- Improved Gastrointestinal Symptoms
- Reduced Tumor Necrosis Factor Alpha